|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2007
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XE07
|
|
gptkbp:bioavailability
|
<1%
|
|
gptkbp:brand
|
Tykerb
Tyverb
|
|
gptkbp:CASNumber
|
231277-92-2
|
|
gptkbp:category
|
protease inhibitor
antineoplastic agent
|
|
gptkbp:chemicalFormula
|
C29H26ClFN4O4S
|
|
gptkbp:combines
|
gptkb:capecitabine
gptkb:letrozole
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:eliminationHalfLife
|
24 hours
|
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lapatinib
|
|
gptkbp:indication
|
advanced or metastatic breast cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits EGFR
inhibits HER2
|
|
gptkbp:metabolism
|
gptkb:CYP3A5
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
581.05 g/mol
|
|
gptkbp:patentExpired
|
2029
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
>99%
|
|
gptkbp:PubChem_CID
|
208908
CHEMBL554
DB01259
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
rash
|
|
gptkbp:target
|
gptkb:EGFR
HER2
|
|
gptkbp:UNII
|
CHC60D1Q58
|
|
gptkbp:usedFor
|
gptkb:cancer
gptkb:HER2-positive_breast_cancer
|
|
gptkbp:bfsParent
|
gptkb:P15056
gptkb:P42338
gptkb:CYP3A5
gptkb:CYP3A4_gene
gptkb:ALTTO_trial
|
|
gptkbp:bfsLayer
|
6
|